Letrozol-Ct Abz-Pharma (Letrozole)

Letrozole blocks the aromatase enzyme, which converts adrenal and peripheral androgens into estrogen. By inhibiting this conversion, circulating estrogen concentrations drop, depriving estrogen‑dependent breast cancer cells of a key growth signal and thereby reducing tumor proliferation.

The specific dose of Letrozol-Ct Abz-Pharma is determined by the treating physician based on the patient’s clinical condition, renal and hepatic function, and other individual factors. Prescribers follow established oncology guidelines and adjust the regimen as needed.

Letrozol-Ct is classified as Pregnancy Category X, meaning it is contraindicated during pregnancy because it can cause fetal harm. It is also not recommended for breastfeeding mothers, as the drug may be excreted in breast milk and affect the infant.

To request Letrozol-Ct Abz-Pharma, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs) and required import documentation.

Letrozol-Ct (letrozole) and other aromatase inhibitors such as anastrozole and exemestane share the same mechanism of reducing estrogen synthesis. Letrozole is often considered the most potent inhibitor, offering slightly greater estrogen suppression, which can translate into marginally improved disease control in some clinical scenarios, though individual response varies.

Letrozol-Ct should be stored at ambient temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight and excessive heat. Do not store in bathrooms or near kitchen appliances that generate steam.

Letrozol-Ct is taken orally, usually as a tablet swallowed whole with water. The medication is typically taken once daily, at the same time each day, and can be taken with or without food, unless the prescriber advises otherwise.

Serious risks include severe liver injury, marked bone loss leading to fractures, and rare thromboembolic events such as deep‑vein thrombosis or pulmonary embolism. Patients should report signs of jaundice, unexplained bone pain, swelling of the legs, or sudden shortness of breath to their healthcare provider promptly.

Letrozol-Ct is contraindicated in pregnant women, nursing mothers, and patients with known hypersensitivity to letrozole or any component of the formulation. Caution is also advised for individuals with severe liver impairment, uncontrolled osteoporosis, or those receiving estrogen replacement therapy.